PMID: 9417717Jan 7, 1998Paper

Cardiovascular gene therapy

Ugeskrift for laeger
P R Hansen

Abstract

Recent insights into the pathogenesis of cardiovascular disease have created the background for development of molecular therapies, and somatic gene transfer and use of antisense oligonucleotides are among the exciting new technologies in this field of research. Gene transfer into the cardiovascular system can be achieved by non-viral or viral vectors, and the latter (i.e., recombinant retrovirus or adenovirus) have the greatest efficacy in vivo. There are several potential clinical applications of gene therapy in cardiovascular disease, and interest has focused on restenosis after angioplasty, critical limb ischaemia, venous bypass graft occlusion, myocardial infarction, and familial hypercholesterolaemia. Favourable results of gene therapy and/or antisense strategies have been reported in experimental models, and these approaches show considerable promise for the treatment of human cardiovascular disease. However, definite clinical efficacy remains to be demonstrated in any gene therapy protocol, and there are many unresolved issues before gene therapy is likely to be implemented in the cardiovascular clinical practice.

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.

Related Papers

Schweizerische medizinische Wochenschrift
F C TannerT F Lüscher
Expert Opinion on Biological Therapy
Uli C Broedl, Daniel J Rader
© 2021 Meta ULC. All rights reserved